Last edition
News about "FDA Approves Subcutaneous Version of Keytruda "
FDA Approves Subcutaneous Version of Keytruda for Solid Tumours
The U.S. Food and Drug Administration (FDA) has granted approval for a new subcutaneous formulation of Merck’s cancer immunotherapy Keytruda, now marketed as Keytruda Qlex.<br />
FDA Approves Subcutaneous Version Of Keytruda | 22/09/2025 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members